SCHEMBL2733151

SCHEMBL2733151

CC(=O)Oc1cccc(Sc2ccc(C(=O)O)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.51
ALDH1A1 P00352 2/20 0.50
HPGD P15428 2/20 0.50
LMNA P02545 3/20 0.49
CYP3A4 P08684 1/20 0.49
GAA P10253 2/20 0.48
RXRA P19793 2/20 0.46
RXRB P28702 2/20 0.46
RARB P10826 1/20 0.46
RARG P13631 1/20 0.46
RXRG P48443 1/20 0.46
ACHE P22303 1/20 0.45
ELANE P08246 1/20 0.45
KDM4E B2RXH2 3/20 0.44
TSHR P16473 2/20 0.44
RAB9A P51151 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
APEX1 P27695 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6935209 0.85 MTNR1A (0.56) ALDH1A1HPGDRXRARXRBRARB
SCHEMBL13049316 0.85 LMNA (0.60) HSD17B10ALDH1A1HPGDLMNACYP3A4
SCHEMBL2707663 0.84 HSD17B10 (0.71) HSD17B10ALDH1A1HPGDLMNAGAA
SCHEMBL2706311 0.81 CYP3A4 (0.47) ALDH1A1HPGDLMNACYP3A4ACHE
SCHEMBL14524425 0.78 HSD17B10 (0.57) HSD17B10ALDH1A1LMNACYP3A4GAA
SCHEMBL685431 0.78 MGLL (0.53) ALDH1A1HPGDRXRARXRBRARB
SCHEMBL1447749 0.77 HPGD (0.66) HSD17B10ALDH1A1HPGDLMNARXRA
SCHEMBL258461 0.77 LMNA (0.68) HSD17B10ALDH1A1LMNACYP3A4GAA
SCHEMBL3422384 0.77 ELANE (0.61) HSD17B10ALDH1A1HPGDLMNAGAA
SCHEMBL29492631 0.77 LMNA (0.68) HSD17B10ALDH1A1LMNACYP3A4GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2435462-A1 NOVEL GLUCOCORTICOID RECEPTOR AGONISTS Pfizer Limited (GB) 2012-04-04 EP disclosed
WO-2010136940-A1 NOVEL GLUCOCORTICOID RECEPTOR AGONISTS PFIZER LIMITED (GB) 2010-12-02 WO disclosed
WO-2010136940-A1 NOVEL GLUCOCORTICOID RECEPTOR AGONISTS PFIZER LIMITED (GB) 2010-12-02 WO disclosed
US-20100303758-A1 Novel Glucocorticoid Receptor Agonists GLOSSOP PAUL ALAN 2010-12-02 US disclosed
US-20100303758-A1 Novel Glucocorticoid Receptor Agonists GLOSSOP PAUL ALAN 2010-12-02 US disclosed
US-20100303758-A1 Novel Glucocorticoid Receptor Agonists GLOSSOP PAUL ALAN 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100303758-A1 Novel Glucocorticoid Receptor Agonists NR3C1, NR3C2, MC2R HSD17B10 712/4885ALDH1A1 2013/4885HPGD 688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.